Anticholinergics May Lead to the Development of Dementia Later in Life - Read by Christos Sierros

NEW YORK - June 25, 2019 - PRLog -- A recent University of Nottingham study involving 58,769 participants that had been diagnosed with dementia, and being 55 years or older, discovered that treatment with potent anticholinergics on a daily basis for 3 years increased the dementia risk from 6% to 49%.

This relationship between daily treatment with potent anticholinergics and dementia risk was found to be even stronger for participants who started treatment before the age of 80, and as well as participants with the specific diagnosis of vascular dementia.

About Anticholinergics

Anticholinergics interfere with the function of neurotransmitter acetylcholine in the peripheral & central nervous systems. They selectively prevent the  neurotransmitter acetylcholine from interacting with its receptor on nerve cells. .

Popular Anticholinergics:

Amitriptyline
Atropine
Benztropine
Chlorpheniramine
Chlorpromazine
Clomipramine
Clozapine
Cyclobenzaprine
Cyproheptadine
Desipramine
Dexchlorpheniramine
Dicyclomine
Diphenhydramine
Doxepin
Fesoterodine
Hydroxyzine
Hyoscyamine
Imipramine
Meclizine
Nortriptyline
Olanzapine
Orphenadrine
Oxybutynin
Paroxetine
Perphenazine
Prochlorperazine
Promethazine
Protriptyline
Pseudoephedrine HCl
Scopolamine
Thioridazine
Tolterodine
Trifluoperazine
Trimipramine
Triprolidine HCl

Read by Christos Sierros (https://www.pinterest.com/ChristosSierros)